buyWeak cluster of 410b5-1 plan
Young Caroline bought $755 of CPIX
director at CUMBERLAND PHARMACEUTICALS INC. 647 shares at an average of $1.17, traded Nov 1, 2024, filed Dec 5, 2024.
Conviction score
20Value
$755
647 shares
Holdings after
29,664
+2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-24-050113, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.15 | $44 | 29,055 | Dec 5, 2024 |
| Nov 4, 2024 | POpen-market purchase Common Stock10b5-1 | +25 | $1.17 | $29 | 29,080 | Dec 5, 2024 |
| Nov 5, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.20 | $46 | 29,118 | Dec 5, 2024 |
| Nov 6, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.20 | $46 | 29,156 | Dec 5, 2024 |
| Nov 7, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.17 | $44 | 29,194 | Dec 5, 2024 |
| Nov 8, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.18 | $45 | 29,232 | Dec 5, 2024 |
| Nov 11, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.20 | $46 | 29,270 | Dec 5, 2024 |
| Nov 12, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.20 | $46 | 29,308 | Dec 5, 2024 |
| Nov 13, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.20 | $46 | 29,346 | Dec 5, 2024 |
| Nov 14, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.19 | $45 | 29,384 | Dec 5, 2024 |
| Nov 15, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.17 | $44 | 29,422 | Dec 5, 2024 |
| Nov 18, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.18 | $45 | 29,460 | Dec 5, 2024 |
| Nov 19, 2024 | POpen-market purchase Common Stock10b5-1 | +38 | $1.15 | $44 | 29,498 | Dec 5, 2024 |
| Nov 20, 2024 | POpen-market purchase Common Stock10b5-1 | +43 | $1.13 | $49 | 29,541 | Dec 5, 2024 |
| Nov 21, 2024 | POpen-market purchase Common Stock10b5-1 | +43 | $1.09 | $47 | 29,584 | Dec 5, 2024 |
| Nov 22, 2024 | POpen-market purchase Common Stock10b5-1 | +16 | $1.07 | $17 | 29,600 | Dec 5, 2024 |
| Nov 25, 2024 | POpen-market purchase Common Stock10b5-1 | +16 | $1.09 | $17 | 29,616 | Dec 5, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stock10b5-1 | +16 | $1.09 | $17 | 29,632 | Dec 5, 2024 |
| Nov 27, 2024 | POpen-market purchase Common Stock10b5-1 | +16 | $1.15 | $18 | 29,648 | Dec 5, 2024 |
| Nov 29, 2024 | POpen-market purchase Common Stock10b5-1 | +16 | $1.32 | $21 | 29,664 | Dec 5, 2024 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth director | $8,209 | 4,716 | |
| 25Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J Chairman and CEO | $1,318 | 769 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Jones James director | $1,318 | 769 | |
| 15Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Young Caroline director | $256 | 154 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth director | $9,348 | 8,029 | |
| 25Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J Chairman and CEO | $1,755 | 1,506 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Jones James director | $1,755 | 1,506 | |
| 15Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth director | $9,106 | 7,107 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J Chairman and CEO | $1,827 | 1,426 | |
| 15Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Jones James director | $1,827 | 1,426 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.